STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Cerluten

Also known as

Cerluten® · A-5 · Cytomax A-5 · peptide complex A-5 · brain bioregulator · brain peptide complex · CNS peptide bioregulator · nerve cell peptides (marketing) · Nature’s Marvels CNS / Central Nervous System Bioregulator (related product line) · Lingual Cerluten (sublingual form discussed)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic Oral Longevity & bioregulators

Whole-body — people treat this as circulating, not a local pin.

What people say Cerluten is an oral bovine CNS/cortex low-molecular-weight peptide complex, commonly described as about 10 mg complex per capsule. It is not a single sequence and is not interchangeable with Cortexin, Cerebrolysin, Pinealon or Cortagen. Doses people talk about
Capsule identityAbout 10 mg peptide complex per capsule

Common product and study description; finished capsule mass includes other material.

Developer study schedule1–2 capsules, 2–3 times/day, for 10–20 days

Small open add-on clinical series, not a blinded dose comparison.

Retail month-course wording1–2 capsules twice daily for about one month

Common export-label wording; meal placement differs from the developer report.

Maintenance-pack convention2 capsules/day for about 10 days

Product and community pack arithmetic, not controlled maintenance evidence.

All rows are oral product or small-series contexts. Capsule-complex milligrams are not convertible to single synthetic peptides.

Half-life & effect duration

Half-life in the body
  • Product half-lifeNo settled estimate
Felt duration people report
  • Post-course vendor / community claimBenefits lasting 3–6 months
  • Firsthand timingNo consistent completed-use timeline reported
Timing context & sources
How it may feel Cerluten is not presented as an acute stimulant. The developer-affiliated series assessed outcomes after a multi-day course and reported no positive effect in 12.5%; the inspected forum discussion supplied no completed Cerluten course log or dependable onset clock.
Cycles people discuss The small clinical series used 10–20-day courses, while retail labels often describe about 30 days. Repeats every 3–6 months or two to three times yearly are product and community traditions, not modern dose-ranging results. Timing Before-meal, with-meal, morning and midday placement varies across the clinical report and labels. No public human pharmacokinetic half-life or single-dose felt window was established. Stacks Cerluten commonly appears in brain-vessel-liver or wider multi-organ kits. Ventfort, Svetinorm, Pinealon, Cortagen and Endoluten can all confound single-product attribution. Watch for Evidence bar: Primary human package is a small open add-on series at the developer-affiliated institute; large blinded modern multi-center RCTs for oral Cerluten are sparse to absent.
Related
CortagenPinealonCerebrolysinVentfortEndoluten

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The inspected clinical report does not establish a Cerluten half-life.

It reports a multi-day oral schedule and outcomes after a course, not single-dose absorption or elimination measurements.

Developer-affiliated, vendor-hosted report of a heterogeneous extract; no independent component-resolved pharmacokinetic study was inspected.

Felt duration people report

No dependable single-dose felt window was established.

The clinical report evaluates a 10–20-day add-on course, and the inspected forum thread repeats product framing without a completed Cerluten experience log.

Open, nonrandomized clinical series with background medications; the community source contains no compound-specific completed self-log.

What people say 16

  • Longevity use: Periodic “brain cytomax” courses in multi-organ Khavinson kits for maintenance — not framed as an acute nootropic buzz. forum
  • Overall clinical rating (open series): Institute write-up: “good” clinical result ~64.6% with Cerluten add-on vs ~27% on general-purpose medicines alone; “satisfactory” ~22.9% vs ~40.5%; “not satisfactory” ~12.5% vs ~32.5% (p reported <0.05 for key contrasts). trial
  • Memory complaints: Subjective memory-disturbance rates reported ~54.5% baseline → ~28.5% after Cerluten course vs ~45.2% after general therapy alone. trial
  • Attention / absent-mindedness: Absent-mindedness complaints ~48.7% → ~14.6% with Cerluten vs ~43.9% general therapy; correction-task curves described as more stable (“warming-up” mid-task, gradual end decline). trial
  • Correction-task throughput: Symbols viewed reported ~1143.7 ± 75.4 pre-treatment → ~1682.6 ± 62.8 after Cerluten vs ~1573.8 ± 67.5 after general medicines; healthy reference ~1835.2 ± 83.7. trial
  • Correction-task errors: Errors reported ~18.12 ± 0.93 pre → ~8.67 ± 0.96 after Cerluten vs ~11.1 ± 0.86 after general medicines; healthy reference ~7.15 ± 1.01. trial
  • Headache: Headache complaint rates ~76.6% → ~34.1% with Cerluten vs ~47.2% general therapy. trial
  • Sleep disturbance: Sleep-disturbance rates ~54.9% → ~24.3% with Cerluten vs ~34.0% general therapy. trial
  • Emotional instability: ~75.8% → ~21.4% with Cerluten vs ~43.0% general therapy (significant vs general therapy in write-up). trial
  • Rapid fatigability: ~72.0% → ~32.4% with Cerluten vs ~53.2% general therapy. trial
  • Stroke / TBI residual notes: Moderate regression of residual focal symptoms, speech-function notes in motor/sensory aphasia contexts, and less muscular spasticity described in the same open series — all as add-on to standard neurology meds. trial
  • EEG / alpha index: Pathological EEG types (III/IV/V) shifted toward clearer alpha-rhythm modulation and restored zonal differences; alpha-index ~34.0 ± 4.1 → ~47.9 ± 3.7 with Cerluten vs ~33.6 ± 3.7 → ~41.3 ± 4.2 with general therapy (healthy ~55.1 ± 3.9). trial
  • Marketing indication lists (not Western approvals): Vendor pages often list atherosclerosis-related brain activity, stroke/TBI rehab, memory/concentration decline, and sometimes broad neurodegenerative or mood labels; these are commercial/Russian-parapharmaceutical framings, not FDA indications. forum
  • Related short-peptide / brain-extract science (not Cerluten-only proof): Broader Khavinson and related work cites antioxidant enzyme upregulation (e.g., SOD2, GPX1, catalase narratives), neurogenesis markers (nestin, GAP43, β-tubulin III, doublecortin in related peptide models), chromatin decondensation in aged lymphocyte cultures, and anti-apoptotic pathway talk — often for related short peptides or cortex preparations, then loosely attributed to Cerluten in secondary blogs. animal
  • What is not proven: No high-quality Western evidence that oral Cerluten treats Alzheimer’s, Parkinson’s, MS, depression as primary therapy, prevents dementia, or extends human lifespan. trial
  • Elderly mental-capacity maintenance: Product and institute recommendations include elderly use for maintaining mental capacity — framing is preventive/supportive course use, not acute rescue. trial

Doses people talk about 14

  • Alternate retail wording: 1–2 capsules 1–2 times daily, often ~30 minutes before meals (or “as directed”), multi-week course. forum
  • 20-capsule maintenance pack math: Common community/vendor pattern: 2 capsules daily for ~10 days (= one 20-cap pack) for “ongoing maintenance,” repeated seasonally. forum
  • 60-capsule bottle math: At 2 caps/day → ~30 days; at 4 caps/day (2×2) → ~15 days; at clinical 2–3×/day with 1–2 caps each → packs empty faster — users often buy multiple bottles for a full intensive + partner stack. forum
  • Nature’s Marvels–style intensive then monthly pulse (class pattern for related bioregulators): Community often mirrors other organ bioregulators: intensive ~2 capsules daily × ~30 days, then ~2 capsules daily × ~10 days each subsequent month — exact Cerluten SKU instructions vary by brand. forum
  • Higher “special needs” doubling talk (class pattern): Some bioregulator guides mention doubling (e.g., 2 caps twice daily intensive) for selected cases — not Cerluten-specific trial dose-finding. forum
  • Gray-market caution: Capsules are not interchangeable without identity/purity checks; mg of “peptide complex,” amino-acid lists, and manufacturing standards can differ across Cytomax-branded vs generic “A-5” sellers. forum
  • No validated “more is better” ladder: Community and skeptical write-ups note absence of controlled dose-response for the extract; stacking multiple organ bioregulators has no controlled factorial support. forum
  • Daily active math (label-style): Recommended daily dose often stated as 2 capsules (= ~20 mg complex) or 4 capsules (= ~40 mg complex). forum
  • Cytomax retail label (common export wording): Adults 1 or 2 capsules 2 times a day during meals; duration ~1 month; may repeat after 3–6 months. forum
  • Course-length disagreement is real: Clinical blocks emphasize 10–20 days at higher daily frequency; many retail labels emphasize ~30 days at 1–2×/day — both circulate; neither is a modern dose-ranging RCT. forum
  • Capsule strength (most-cited clinical / product description): ~10 mg peptide complex A-5 (active peptide complex) per capsule; finished capsule mass is higher (excipients). trial
  • Clinical series schedule (highest-frequency documented human use): 1–2 capsules, 2–3 times per day, before meals, for 10–20 days depending on intensity of pathology, as add-on to general-purpose neurology meds (St. Petersburg Institute Medical Center, Oct 2003–Feb 2004). trial
  • Institute recommendation wording: Per os, ~10–15 minutes before meals, 1–2 capsules 2–3 times daily for 10–20 days; optional further course after ~3–6 months. trial
  • Framing: Discussed research, institute-report, and vendor-label ranges only — not medical advice, not prescriptions, not safety-certified Western protocols. forum

How it may feel 8

  • Days 1–7: Little acute buzz for most; subtle clarity / less fog talk if anything — not stimulation or same-day focus drugs. forum
  • Vendor “one-month” runs: Retail labels often push ~30-day courses at lower daily frequency than the intensive clinical 2–3×/day pattern; users who notice anything often place it mid-to-late course. forum
  • After stopping: Bioregulator lore claims steadier cognition for weeks to a few months after a pulsed course; others say effects fade quickly — residual benefit is not measured PK. anecdote
  • Stacked multi-cytomax courses: When taken with Ventfort / Svetinorm / Endoluten / other organs, single-agent feel is uninterpretable; lifestyle and co-meds dominate attribution. forum
  • No change after one course: Community checklist: sleep/stress/BP, expectation mismatch (not a stimulant), product authenticity/purity, capsule strength labeling differences, and whether they ran a short intensive vs sparse maintenance pack — not automatic dose escalation. forum
  • Weeks 1–2 (clinical block length): Institute courses ran ~10–20 days; functional gains and complaint reductions were assessed after the course, not as day-one effects. trial
  • End of course: Reassess memory, attention, sleep, headache/fatigue burden; non-responders are expected in both the ~12.5% “not satisfactory” clinical arm and community anecdotes. trial
  • Months 3–6: Common re-run window per institute “another course in 3–6 months” and vendor repeat language; ~2–3 courses/year is the usual longevity pattern. trial

Cycles people discuss 8

  • Retail month courses: ~1-month (≈30 day) oral courses appear widely on product labels. forum
  • Yearly rhythm: Longevity users often run ~2–3 courses per year rather than indefinite daily use. forum
  • Pulsed vs continuous: Pulsed cytomax courses are preferred in Khavinson culture; continuous multi-year daily use has thin dedicated evidence. forum
  • Maintenance mini-courses: 10-day / 20-capsule packs used between fuller courses for “healthy maintenance” talk. forum
  • Multi-bioregulator alignment: When stacked with other Cytomaxes, users often align the same multi-week on-block calendar across organs. forum
  • Time off: Off-periods between courses are default; residual-effect lore is the usual justification for not dosing year-round. forum
  • Clinical blocks: 10–20 day oral courses are the most-cited research schedule. trial
  • Repeat interval: Institute and vendors commonly suggest another course after ~3–6 months. trial

Timing 7

  • PK data: No solid public human half-life or bioavailability numbers for the multi-peptide Cerluten complex as a single entity. forum
  • Why courses exist in the narrative: Framed as gene-expression / tissue-regulation effects that may outlast circulating peptide presence — bioregulator story, not measured multi-compartment PK. forum
  • Residual-window talk: Vendor/community claims of benefits lasting ~3–6 months after a course are conventional bioregulator marketing, not Cerluten-specific PK studies. forum
  • Clock preferences: Morning/midday pre-meal dosing more common when cognition is the goal; bedtime-only regimens less standard for Cerluten (contrast some pineal-line products). forum
  • Multi-dose days: Clinical use split several capsules/day over short courses, consistent with short oral exposure rather than weekly inject scheduling. trial
  • Downstream assessment: Attention/memory/EEG changes were tracked after multi-day courses, not as “still circulating” drug levels. trial
  • Food timing conflict: Institute clinical wording often ~10–15 min before meals; some retail labels say during meals — both appear on real products. trial

More on what it is 9

  • Not a single sequence: Unlike Cortagen (synthetic AEDP), Pinealon (synthetic EDR), or Epitalon (synthetic AEDG), Cerluten remains a multi-fraction natural extract; precise active constituents and relative contributions are not fully characterized as one defined drug substance. forum
  • AEDG / Epitalon mix-up: Some marketing blurs Cerluten with AEDG (Ala-Glu-Asp-Gly / Epitalon). Independent explainers note AEDG is the pineal-line tetrapeptide; the defined synthetic cortex analog derived from cortex-extract work is Cortagen (AEDP, Ala-Glu-Asp-Pro) — not AEDG. forum
  • Why people use it: Memory, attention, mental stamina, “brain aging,” and pulsed longevity cytomax kits; also searched next to post-stroke / TBI recovery narratives from institute write-ups. forum
  • Cortexin vs Cerluten honesty: Heavier stroke/TBI clinical literature is often for the registered injectable cattle cerebral-cortex preparation Cortexin (and synthetic Cortagen), not automatically transferable to oral Cerluten capsules. forum
  • What it is not: Not a stimulant, not an FDA-approved Alzheimer’s / stroke / TBI drug, not Cortexin itself, not Cerebrolysin, not Pinealon, not Cortagen, not Epitalon. forum
  • Skeptic note: Treat “no side effects / no contraindications” and broad benefit lists as manufacturer/institute narrative until independently replicated; gray-market identity and purity remain open variables. forum
  • What it is: Cerluten® is Cytomax A-5 — a complex of low-molecular-weight peptides (MW typically described up to ~10,000 Da / ~10 kDa) isolated from CNS / cerebral cortex tissue of young calves (often stated ≤12 months of age), sold primarily as oral capsules with ~10 mg peptide complex A-5 per capsule. trial
  • Mechanism talk: Tissue-specific brain-cell metabolism, antioxidant / peroxide-oxidation regulation in cortex, and gene-expression / chromatin narratives (DNA-promoter and histone interaction claims for short peptides in the Khavinson framework) — not classic surface-receptor agonism like a stimulant. trial
  • Evidence posture: Best-cited human package is a small open-label St. Petersburg Institute add-on series (2003–2004; n=48 vs 37 general-therapy controls) — not large Western multi-center blinded RCTs. Related animal/in-vitro work often cites broader brain-peptide or short-peptide families rather than Cerluten alone. trial

Stacks 10

  • Classic Khavinson CNS triad: Cerluten (A-5, brain) + Ventfort (A-3, vascular) + Svetinorm (A-7, liver) — marketed as brain + blood-flow + metabolic-clearance axis; sold separately or as combined “Neuro-3” / nervous-system complexes. Ratios/schedules are brand-defined, not RCT-optimized. forum
  • Vascular pair alone: Cerluten + Ventfort when the narrative is cerebral perfusion + brain peptides without full liver cytomax. forum
  • Pinealon: Often paired or compared — synthetic EDR short peptide vs natural multi-fraction Cerluten; different molecules, overlapping cognition marketing. forum
  • Cortagen adjacency: Synthetic AEDP cortex tetrapeptide discussed as the defined analog lineage of cortex extracts; some users rotate or compare rather than co-run both blindly. forum
  • Endoluten / pineal line: Multi-organ longevity kits pair brain cytomax with pineal bioregulator for sleep/circadian + cognition narratives. forum
  • Vladonix / thymus and other Cytomaxes: Seasonal “system reset” stacks (thymus, vessels, liver, brain) — high confound for attributing any one product. forum
  • Epitalon confusion stack: Some longevity stacks run Epitalon + Cerluten under “brain + telomere/pineal” logic; do not equate Cerluten with AEDG. forum
  • Semax / Selank: Minority Western-forum stacks next to Russian peptide nootropics — different mechanisms and evidence bases. forum
  • Lifestyle co-credit: Sleep, blood-pressure control, aerobic exercise, and cognitive training are often co-credited and dominate evidence-based brain health. forum
  • Nootropics nearby: Piracetam-class, vinpocetine-class, and other agents appear in the same institute “general purpose” background therapy — confounds single-agent causality. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 12

  • Animal-tissue origin risks: Theoretical allergy, batch contamination, prion/species-QC, and manufacturing-control concerns apply to bovine CNS extracts even when marketers claim high biocompatibility. forum
  • Source / gray-market risk: Multi-brand “A-5 / Cerluten” capsules may differ in identity, peptide content, and contaminants; storage rules ≠ COA. forum
  • Regulatory status: Sold as research/dietary bioregulator or Russian parapharmaceutical lines in various markets — not FDA-approved for stroke, TBI, dementia, Alzheimer’s, Parkinson’s, MS, or cognition enhancement. forum
  • Marketing vs molecule gap: Epigenetic/DNA-binding and broad disease lists on sales pages can outrun independent lab characterization of a given capsule’s contents. forum
  • Class bioregulator mild AE talk: Across oral peptide bioregulators, minority reports of mild GI upset, bloating, temporary fatigue, or mild headache appear in general bioregulator side-effect guides — not Cerluten-specific RCT rates. forum
  • Pregnancy / lactation / intolerance: General Khavinson-product caution language often lists individual intolerance, pregnancy, and lactation as avoid contexts — treat as class caution, not Cerluten-trial data. forum
  • Interactions: No robust published interaction tables vs antidepressants, anticoagulants, anticonvulsants, or nootropics; institute narrative claims compatibility with common neurology meds but without modern interaction science. forum
  • Do not substitute for acute care: Stroke, TBI, seizure, progressive dementia workups, and emergency neurology are not DIY bioregulator domains. forum
  • Cortexin evidence leakage: Using Cortexin IM stroke data as if it proves oral Cerluten efficacy is a common category error. forum
  • Evidence bar: Primary human package is a small open add-on series at the developer-affiliated institute; large blinded modern multi-center RCTs for oral Cerluten are sparse to absent. trial
  • Institute “no AEs” claim: Series reported no negative influences, no side effects, no drug dependence, and “no contraindications” for study conduct — this is not a long-term Western safety database or ICH-standard toxicology package. trial
  • Open-label confounds: Patients continued standard neuro meds; subjective endpoints and lack of blinding inflate uncertainty about single-agent effect size. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →